Economic Observation Network Merck's stock price rose on July 16th, as its new oral cholesterol lowering drug was approved by the FDA and its pipeline layout progress was recognized by the market

Recent Stock Trends
On July 16th, MRK. US rose 3.25% to $127.63, directly catalyzed by its new oral cholesterol lowering drug Lipfendra, which received FDA approval 。

Product Development Progress
This drug is the first approved oral PCSK9 inhibitor in the United States, which is more convenient to use than injectable forms and priced nearly half cheaper than similar products. Wall Street analysts predict that its peak annual revenue could reach $4.2 billion This approval has added important long-term growth points to the company's product line.

Strategic Advancement
The deeper driving logic lies in the market's increased expectations for its successful response to the "drug king" Keytruda patent cliff. The company has recently significantly expanded its pipeline through large-scale mergers and acquisitions (such as Cidara and Terns) and internal research and development, aiming to lay out ahead of the expiration of Keytruda patents in 2028 The approval of oral PCSK9 drug this time is one of the achievements of its pipeline diversification strategy, which alleviates market concerns about dependence on a single product.

The above content is based on publicly available information and does not constitute investment advice.